Back3D Global Biotech Overview

3D Global Biotech Other Current Assets

3D Global Biotech's other current assets is $18M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$18.35M
↑ 50.90% YoYΔ $6.19M vs prior year quarter

Peer average / median

Loading

3D Global Biotech Other Current Assets History

Loading

3D Global Biotech vs. peers: Other Current Assets Comparison

Loading

3D Global Biotech Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

3D Global Biotech (6808.TWO) FAQ

The latest other current assets for 6808.TWO is $18M as of June 2026. That compares with $12M in the prior-year period — up 50.9% year over year. Investors often review this figure alongside 3D Global Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6808.TWO's other current assets moved from $12M to $18M — a 50.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 3D Global Biotech's operating scale or balance-sheet position.

A other current assets figure of $18M for 6808.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 6808.TWO's other current assets ($18M), review year-over-year change from $12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack 3D Global Biotech's other current assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.